Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 960 participants.
Also called NCT04250116
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 960 participants
- Sponsor
- Registry
-
NCT04250116
-
- Other papers using this trial's data
- Antithrombotic Therapy in Patients With Atrial Fibrillation With Prior Complex PCI: A Secondary Analysis of the Randomized ADAPT AF-DES Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04250116. Randomized; no masking; primary purpose treatment. Start 2020-04-28 (actual); primary completion 2026-05-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- NOAC monotherapy
- Intervention (Drug)
- Dual antithrombotic therapy with NOAC and clopidogrel
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct04250116- Content hash
31e55e4a4b299171963dbe4683ee1921cbd26f03f0510e92b6132f65c83a3ba0